Lotus Pharmaceuticals, Inc. Announces Fourth Quarter and Fiscal Year 20...(ESTING ACTIVITIES ...),Health

ACTIVITIES 679,237 1,242,262

CASH FLOWS FROM FINANCING ACTIVITIES:

Net proceeds from convertible debt 2,950,000 --

Payment of debt issuance costs (231,526) --

Repayments of related party advances (816,732) (737,291)

Repayments of notes payable

- related parties 509,351 (3,456,196)

NET CASH PROVIDED BY (USED IN)

FINANCING ACTIVITIES 2,411,093 (4,193,487)

NET INCREASE IN CASH 2,239,875 1,928,222

EFFECT OF EXCHANGE RATE ON CASH 228,926 44,805

CASH - beginning of year 2,089,156 160,934

CASH - end of year $4,557,957 $2,089,156

SUPPLEMENTAL DISCLOSURE OF CASH

FLOW INFORMATION:

Cash paid for:

Interest $477,001 $325,824

Income taxes $-- $--

Non-cash investing and

financing activities:

Due from related party offset

against note payable - related

parties $813,650 $--

Common stock issued for conversion

of convertible debt $230,000 $--

Debt discount for grant of warrants

and beneficial conversion feature $1,616,839 $--

Intangible assets for related

party liabilities $-- $1,127,551

LOTUS PHARMACEUTICALS, INC. AND SUBSIDIARIES

RECONCILIATION OF NON-GAAP FINANCIAL DATA

For the Three Months For the Three Months

'/>"/>